{"id":"captodiame","rwe":[],"tags":[{"label":"captodiame","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"N05BB02","category":"atc"},{"label":"Active","category":"status"},{"label":"Anxiety disorder","category":"indication"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"captodiam","offLabel":[],"synonyms":["captodiamine hydrochloride","captodiame","captodiam","captodiamin","captodiamine","captodramin","captodramine","captodiamine HCl"],"timeline":[],"brandName":"Captodiam","ecosystem":[{"indication":"Anxiety disorder","otherDrugs":[],"globalPrevalence":301000000}],"mechanism":{"modality":"Small Molecule","drugClass":"captodiame","explanation":"In simple terms, Captodiam helps to calm the brain by influencing the levels of certain chemicals, such as serotonin and dopamine, which play a role in regulating emotions and mood.","oneSentence":"Captodiam works by modulating the activity of certain neurotransmitters in the brain.","technicalDetail":"Captodiam is believed to exert its effects by interacting with the central nervous system, specifically at the level of the brain, where it influences the activity of neurotransmitters involved in the regulation of anxiety and stress responses."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/483","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CAPTODIAME","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:10:41.366141","biosimilars":[],"competitors":[{"drugName":"hydroxyzine","drugSlug":"hydroxyzine","fdaApproval":"1956-04-12","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"captodiame","indications":{"approved":[{"name":"Anxiety disorder","source":"DrugCentral","snomedId":197480006,"regulator":"FDA","usPrevalence":40000000,"globalPrevalence":301000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2022"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"hydroxyzine","brandName":"hydroxyzine","genericName":"hydroxyzine","approvalYear":"1956","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005298","UNII":"H93K9455DD","CHEBI":"CHEBI:135521","INN_ID":"625","RXNORM":"236176","UMLSCUI":"C0301409","ChEMBL_ID":"CHEMBL2110809","KEGG_DRUG":"D07316","DRUGBANK_ID":"DB09014","PUBCHEM_CID":"10240","SNOMEDCT_US":"4025009","MESH_SUPPLEMENTAL_RECORD_UI":"C495502"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":3,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N05BB02","allCodes":["N05BB02"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Captodiam, also known as CAPTODIAME, is a small molecule drug in the captodiame class. It is used to treat anxiety disorder. The commercial status of Captodiam is unclear, and it is not known if it is patented or available as a generic. Further information on its approval status, half-life, bioavailability, and generic manufacturers is not available. As a result, key safety considerations and pharmacological details are also unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}